Shots:

• The US FDA has approved Benlysta (BLyS-specific inhibitor) for the treatment of active LN who received standard therapy in children aged 5 to 17yrs.
• The main objective of treating lupus nephritis in both adults and children is to maintain renal function while reducing side effects from treatment and associated morbidity
• Benlysta is a human mAb that binds to soluble BLyS. The therapy has the potential to suppress B cell survival incl. autoreactive B cells and slows down the development of B cells into immunoglobulin-producing plasma cells by binding to BLyS

Ref: Businesswire | Image: GSK